2026-526212-37-00招募中3 期
Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1
- 试验地点
- 1
研究概览
简要总结
To evaluate the long-term safety of patients with advanced lymphoid leukemia who have been previously administered with UCART19.
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 18-64 Years, 0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained prior any study-specific procedure (patient or parent(s) or legal representative).
- •Patient dosed with UCART19 who completed or discontinued early from a sponsored or from any investigator-initiated study that tested UCART19, or patients who were administered UCART19 under a special access scheme (compassionate use).
- •Female patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners for a 12-month duration after the last UCART19 administration.
排除标准
- •No exclusion criteria for this study.
研究者
Clinical Studies Department
Scientific
Institut De Recherches Internationales Servier IRIS
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic LeukemiaLeukemiaNCT07258043Hospital General de Mexico45
尚未招募
不适用
This study will test if giving prophylactic antibiotics can reduce infections and improve safety for children with acute lymphoblastic leukemia during the early intensive phase of chemotherapyCTRI/2025/10/095772Sonali Aggarwal118
进行中（未招募）
不适用
A Retrospective Real-World Study Based on RATIONALE-307NCT07478809Cancer Institute and Hospital, Chinese Academy of Medical Sciences109
招募中
1 期
Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyPersonalized Active ImmunotherapyMaintenance TherapyAcute Myeloid LeukemiaNCT07551037Fujian Medical University Union Hospital90
招募中
1 期
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT07306832AbbVie18